Sandoz Creates New Global Biosimilar Unit
Sandoz has announced the creation of a new biosimilar development, manufacturing and supply unit.
Sandoz
Sandoz Opens Antibiotic Production Facility in Austria
Sandoz, a generic and biosimilar medicines manufacturer, recently opened a new production facility in Kundl, Austria, to serve more patients with affordable life-saving drugs produced entirely in Europe.
Sandoz Acquires Ophthalmology Franchise from Coherus
In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.
Sandoz Spin-off from Novartis to Start on October 4, 2023
Novartis today confirmed the plan to spin off 100% of its generic drugs arm Sandoz, with trading of the new company’s shares as well as ADRs (American Depositary Receipts) to start on Oct. 4, 2023.
Sandoz in Biosimilars Pact with Just – Evotec Biologics
As Novartis moves toward shedding generics subsidiary Sandoz, which it touts as a global leader in off-patent generic and biosimilar drugs, Sandoz has agreed a multi-year strategic partnership with Just –Evotec Biologics, the Seattle, Washington-based US subsidiary of Germany’s Evotec, to develop and manufacture biosimilars.
Sandoz Builds Biologics Plant in Slovenia
Sandoz, the generics and biosimilars arm of Swiss drugmaker Novartis, has signed a Memorandum of Understanding to build a biologics production plant in Lendava, Slovenia.
Sandoz Invests in Extra European Antibiotic Capacity
Sandoz, the generics arm of Swiss drugmaker Novartis, has announced plans to spend an additional €50 million on raising European manufacturing capacity for finished dosage forms of amoxicillin and other key penicillin products.
Novartis to Shutter a Sandoz US Plant
In advance of the planned spinoff of generics subsidiary Sandoz into a standalone generics producer, Novartis has announced it is closing one of the subsidiary’s US plants.
Novartis Definitely Plans to Spin off Sandoz
Novartis has finally confirmed definite plans to spin off its generic drugs arm Sandoz.
Sandoz Launches Generic Combigan Drops
Novartis subsidiary Sandoz has launched a generic version of Combigan, the ocular hypertensiondrug made by AbbVie’s Allergan arm. The copy of the off-patent eye drops will be marketed only in the US, where Allergan racked up sales of $373 million with the original product in 2021.
Private Equity Buyers Seen as Circling Sandoz
US private equity firms Blackstone and Carlyle may make a joint offer for the Novartis generics unit Sandoz, Bloomberg reports. With six other possible bidders seen as circling Basel-based Sandoz, the news agency’s sources said this sale could shape up to be one of the biggest-ever buyout deals, valued at around $25 billion.
Novartis May Have Sandoz Buyer on the Hook
Novartis and market watchers alike have been dropping repeated hits that a sale of the Swiss drugs giant’s Sandoz-branded generic drugs arm may be closer than has been hinted up to now. In an interview with German weekly news magazine Wirtschaftswoche last week, CEO Vas Narasimhan said, however, that beyond several requests for information no concrete offers are currently on the table.
BASF Invests in Enzymes in Austria
BASF is investing in its enzymes business at the Novartis Kundl/Schaftenau Campus in Austria. The German chemical giant said the agreement with the Swiss group – for which financial details were not disclosed – will enable it to develop a world-scale operation for bacterial enzymes and biotechnology products.
Sandoz to Aquire GSK’s Cephalosporin Antibiotics
Sandoz, the generics division of Swiss drugmaker Novartis, is picking up GlaxoSmithKline’s cephalosporin antibiotics business, including the brands Zinnat, Zinacef and Fortum, for up to $500 million.
